The COVID-19 VaccinE Response and Co-Administration in Rheumatology Patients (COVER-CoAd)

PHASE4Active, not recruitingINTERVENTIONAL
Enrollment

129

Participants

Timeline

Start Date

October 11, 2022

Primary Completion Date

April 1, 2025

Study Completion Date

August 31, 2026

Conditions
Rheumatic Diseases
Interventions
BIOLOGICAL

Hepatitis A vaccine

Vaccination series administered to prevent hepA infection.

BIOLOGICAL

Diphtheria, pertussis, and tetanus booster vaccine

Vaccination booster administered to prevent diphtheria, pertussis, and tetanus

Trial Locations (13)

16635

Altoona Center for Clinical Research, Duncansville

33169

Ocean Wellness Center, Miami Gardens

33569

Southwest Florida Rheumatology, Riverview

35473

Center for Rheumatic Diseases, Northport

38555

Cumberland Rheumatology, Crossville

55121

St. Paul Rheumatology, Eagan

60657

Ravenswood Rheumatology, Chicago

70112

University Medical Center - New Orleans/LSU, New Orleans

77382

Advanced Rheumatology of Houston, Woodland

83702

St. Luke's Rheumatology, Boise

85381

Sun Valley Arthritis, Peoria

88101

Jayashree Sinha, MD, Clovis

97239

Oregon Health & Science University, Portland

All Listed Sponsors
lead

Oregon Health and Science University

OTHER

NCT05543642 - The COVID-19 VaccinE Response and Co-Administration in Rheumatology Patients (COVER-CoAd) | Biotech Hunter | Biotech Hunter